Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

78
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
78
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

79
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
79
Drug Regulation01:25

Drug Regulation

2.5K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

962
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
962
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

88
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
88

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concurrent Insomnia and Suicidal Ideation and Behavior as Psychiatric Adverse Effects of Clozapine Versus Other Atypical Antipsychotics.

Crisis·2026
Same author

Insomnia Symptoms and Psychopathology in Individuals at Clinical High Risk for Psychosis.

Early intervention in psychiatry·2026
Same author

Herpes simplex virus type 1 isolated from newborns reveals viral diversity between and within patients.

The Journal of infectious diseases·2026
Same author

Increasing the Probability of Comparing Between Traditional Medicare and Medicare Advantage.

Health literacy research and practice·2026
Same author

Clozapine-Induced "Pseudo-Agranulocytosis": Bone Marrow Suppression or Increased Neutrophil Margination?

Schizophrenia bulletin·2026
Same author

Randomized Experiments to Foster Trust in Primary Care Doctors.

Journal of general internal medicine·2026

Related Experiment Video

Updated: Nov 17, 2025

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

683

Time to Revisit a Voluntary FDA Comparative Effectiveness Pathway.

Brian J Miller1,2, Vrushab Gowda3,4, Jodi B Segal5,6

  • 1Division of Hospital Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Meyer 8-134-H, Baltimore, MD, 21287, USA. brian@brianjmillermd.com.

Therapeutic Innovation & Regulatory Science
|February 11, 2021
PubMed
Summary

This article reviews past attempts to incorporate comparative effectiveness research into the Food and Drug Administration (FDA) drug approval process. It identifies industry hurdles and proposes future strategies for integrating this research.

Keywords:
Comparative effectiveness researchFDA regulationInnovationReal world evidence

More Related Videos

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.1K
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.7K

Related Experiment Videos

Last Updated: Nov 17, 2025

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

683
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.1K
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.7K

Area of Science:

  • Health Policy
  • Pharmaceutical Sciences
  • Regulatory Science

Background:

  • Recent policy discussions highlight the importance of drug pricing and pharmaceutical innovation.
  • Integrating comparative effectiveness research (CER) into the FDA drug review process has been a long-standing policy goal.
  • Previous policy initiatives aimed at CER integration occurred over a decade ago.

Purpose of the Study:

  • To examine the historical context of integrating comparative effectiveness research into the FDA drug review process.
  • To characterize the challenges faced by the pharmaceutical industry in adopting CER.
  • To propose a viable path forward for CER integration.

Main Methods:

  • Historical policy analysis.
  • Review of previous legislative and regulatory efforts.
  • Qualitative assessment of industry challenges.

Main Results:

  • Past efforts to integrate CER into the FDA drug review process faced significant obstacles.
  • Industry challenges primarily revolved around data requirements, methodological standardization, and potential impacts on innovation.
  • A clear path forward requires addressing these industry concerns and refining policy frameworks.

Conclusions:

  • The integration of comparative effectiveness research into the FDA drug review process is complex.
  • Addressing industry challenges is crucial for successful implementation.
  • A phased approach and stakeholder collaboration are recommended for future policy development.